HYPD

Hyperion DeFi, Inc. Common Stock

13.23 USD
+0.64
5.08%
At close Jul 11, 4:00 PM EDT
After hours
13.12
-0.11
0.83%
1 day
5.08%
5 days
-3.64%
1 month
292.58%
3 months
1,292.63%
6 months
72.27%
Year to date
37.81%
1 year
-83.41%
5 years
-93.78%
10 years
-98.33%
 

About: Hyperion DeFi Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.

Employees: 57

0
Funds holding %
of 7,312 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

4,767% more call options, than puts

Call options by funds: $146K | Put options by funds: $3K

8.29% more ownership

Funds ownership: 4.98% [Q4 2024] → 13.26% (+8.29%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

53% less funds holding

Funds holding: 38 [Q4 2024] → 18 (-20) [Q1 2025]

62% less capital invested

Capital invested by funds: $804K [Q4 2024] → $306K (-$498K) [Q1 2025]

87% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 23

93% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 14

Research analyst outlook

We haven’t received any recent analyst ratings for HYPD.

Financial journalist opinion

We haven’t received any recent news articles for HYPD.

Charts implemented using Lightweight Charts™